Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | OXTR | P30559 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29381363 | 1.00 | LRRK2 (0.37) | LRRK2LMNATP53OXTRMEN1 | |
| SCHEMBL22323690 | 0.88 | LRRK2 (0.42) | LRRK2OXTRMEN1CYP1A2MAPT | |
| SCHEMBL29447061 | 0.88 | LRRK2 (0.42) | LRRK2OXTRMEN1CYP1A2MAPT | |
| SCHEMBL22323745 | 0.78 | LRRK2 (0.41) | LRRK2LMNATP53OXTRMEN1 | |
| SCHEMBL29509324 | 0.78 | LRRK2 (0.41) | LRRK2LMNATP53OXTRMEN1 | |
| SCHEMBL22323952 | 0.77 | LRRK2 (0.34) | LRRK2 | |
| SCHEMBL28650123 | 0.71 | CSF1R (0.39) | MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL29380889 | 0.71 | OXTR (0.51) | LMNATP53OXTRSYKALDH1A1 | |
| SCHEMBL28705520 | 0.71 | EGFR (0.33) | — | |
| SCHEMBL25294394 | 0.69 | GAA (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612397-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-11845744-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20230009712-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20220048902-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2022-02-17 | — | — | US | disclosed |
| US-20220048902-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2022-02-17 | — | — | US | disclosed |
| EP-3920917-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3920915-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| WO-2020163405-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| WO-2020163248-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612397-B2 | Methods and compositions for modulating splicing | SF3B1, SF3B2, SF1 | LRRK2 2529/4885LMNA 404/4885TP53 2844/4885 |
| US-20220048902-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | LRRK2 2215/4885LMNA 246/4885TP53 1686/4885 |
| US-20230009712-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | LRRK2 2215/4885LMNA 246/4885TP53 1686/4885 |
| US-11845744-B2 | Methods and compositions for modulating splicing | RBM17, SF3B1, SF3B5 | LRRK2 2215/4885LMNA 246/4885TP53 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.